{"id":1351,"date":"2009-11-16T11:47:40","date_gmt":"2009-11-16T16:47:40","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/arbiter-6-halts%c2%a0will-you-change-your-practice-will-you-halt-your-use-of-ezetimibe\/"},"modified":"2011-07-19T17:45:09","modified_gmt":"2011-07-19T21:45:09","slug":"arbiter-6-halts%c2%a0will-you-change-your-practice-will-you-halt-your-use-of-ezetimibe","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2009\/11\/16\/arbiter-6-halts%c2%a0will-you-change-your-practice-will-you-halt-your-use-of-ezetimibe\/","title":{"rendered":"ARBITER 6-HALTS:\u00a0Will you change your practice? Will you halt your use of ezetimibe?"},"content":{"rendered":"<p>ARBITER 6-HALTS\u00a0provides provocative information and suggests that niacin is the preferred secondary agent once statin therapy is maxed out in high-risk CAD patients with low HDL levels (for the study, go <a href=\"http:\/\/cardioexchange.org\/nejm\/content\/full\/361\/22\/2113\">here<\/a>; for editorials, go\u00a0<a href=\"http:\/\/cardioexchange.org\/nejm\/content\/full\/361\/22\/2180\">here<\/a>\u00a0and <a href=\"http:\/\/cardioexchange.org\/nejm\/content\/full\/361\/22\/2178\">here<\/a>; for a summary and analysis of the study, go <a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/jwatch\/cardiology\/content\/full\/2009\/1115\/1\">here<\/a>; and for a question-and-answer session with the author,\u00a0go <a href=\"http:\/\/cardioexchange.org\/blogPost?postId=185\">here<\/a>). For me, however, until outcome studies confirm these findings, we cannot lose focus on the fact that\u00a0LDL is the primary target of preventive therapy . Nor can we lose focus on all of the other evidence-based approaches that definitively provide benefit including ASA, hypertension control, and smoking cessation. <\/p>\n<p>DISCLOSURE: Dr. Foody is a consultant to and on the advisor&#8217;s and speaker&#8217;s boards for Merck &amp; Co.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ARBITER 6-HALTS\u00a0provides provocative information and suggests that niacin is the preferred secondary agent once statin therapy is maxed out in high-risk CAD patients with low HDL levels (for the study, go here; for editorials, go\u00a0here\u00a0and here; for a summary and analysis of the study, go here; and for a question-and-answer session with the author,\u00a0go here). [&hellip;]<\/p>\n","protected":false},"author":169,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,7],"tags":[],"class_list":["post-1351","post","type-post","status-publish","format-standard","hentry","category-general","category-prevention"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1351","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/169"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=1351"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1351\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=1351"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=1351"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=1351"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}